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ABSTRACT
Objectives: To study whether systematic reviewers
apply procedures to counter-balance some common
forms of research malpractice such as not publishing
completed research, duplicate publications, or selective
reporting of outcomes, and to see whether they
identify and report misconduct.
Design: Cross-sectional analysis of systematic reviews
and survey of their authors.
Participants: 118 systematic reviews published in
four journals (Ann Int Med, BMJ, JAMA, Lancet), and
the Cochrane Library, in 2013.
Main outcomes and measures: Number (%) of
reviews that applied procedures to reduce the impact
of: (1) publication bias (through searching of
unpublished trials), (2) selective outcome reporting (by
contacting the authors of the original studies), (3)
duplicate publications, (4) sponsors’ and (5) authors’
conflicts of interest, on the conclusions of the review,
and (6) looked for ethical approval of the studies.
Number (%) of reviewers who suspected misconduct
are reported. The procedures applied were compared
across journals.
Results: 80 (68%) reviewers confirmed their data. 59
(50%) reviews applied three or more procedures; 11
(9%) applied none. Unpublished trials were searched
in 79 (66%) reviews. Authors of original studies were
contacted in 73 (62%). Duplicate publications were
searched in 81 (69%). 27 reviews (23%) reported
sponsors of the included studies; 6 (5%) analysed
their impact on the conclusions of the review. Five
reviews (4%) looked at conflicts of interest of study
authors; none of them analysed their impact. Three
reviews (2.5%) looked at ethical approval of the
studies. Seven reviews (6%) suspected misconduct;
only 2 (2%) reported it explicitly. Procedures applied
differed across the journals.
Conclusions: Only half of the systematic reviews applied
three or more of the six procedures examined. Sponsors,
conflicts of interest of authors and ethical approval remain
overlooked. Research misconduct is sometimes identified,
but rarely reported. Guidance on when, and how, to report
suspected misconduct is needed.
INTRODUCTION
Rationale
Research misconduct can have devastating
consequences for public health1 and patient
care.2 3 While a common deﬁnition of
research misconduct is still lacking, there is
an urgent need to come up with strategies to
prevent it.4 5 Fifteen years ago, Smith6 pro-
posed ‘a preliminary taxonomy of research
misconduct’ describing 15 practices ranging
from ‘minor’ to ‘major’ misconduct. Some of
these practices, however, are very common
and may not be regarded by all as ‘miscon-
duct’. Therefore, this research deﬁnes ‘mal-
practice’ as relatively common and minor
misconduct, while the term ‘misconduct’ is
used for data fabrication, falsiﬁcation, pla-
giarism or any other intentional
malpractices.
It has been shown that some of the 15 mal-
practices described by Smith, threaten the
conclusions of systematic reviews. Examples
of such malpractices include: avoiding the
publication of a completed research,7 8
Strengths and limitations of this study
▪ This study combines quantitative and qualitative
methods to investigate how systematic reviewers
deal with research malpractice and misconduct.
▪ It proposes clear and reproducible samples of
systematic reviews from four major medical jour-
nals and the Cochrane Library.
▪ The extracted data were confirmed by 70% of
the authors of the systematic reviews analysed.
▪ The systematic reviewers were not asked to
confirm all their data, but only the information
considered ambiguous.
▪ There is currently no common definition of
‘research misconduct’. This may have led to an
underestimation of its real prevalence.
Elia N, et al. BMJ Open 2016;6:e010442. doi:10.1136/bmjopen-2015-010442 1
Open Access Research
duplicate publications,9 selectively reporting on out-
comes or adverse effects,10 and presenting biased results
that are in favour of the sponsors’11 or the authors’12
interests. The impact of other malpractices, such as gift
or ghost authorship, is less clear.
Rigorous systematic review methodology includes spe-
ciﬁc procedures that can counter-balance some of the
research malpractice. Unpublished studies may, for
example, be identiﬁed through exhaustive literature
searches,13 and statistical tests or graphical displays such
as funnel plots can quantify the risk of publication
bias.14 Unreported outcomes may be unearthed by con-
tacting the authors of original articles, and multiple pub-
lications based on the same cohort of patients can be
identiﬁed and excluded from analyses.15 Authors of sys-
tematic reviews (further called: systematic reviewers or
reviewers) can also use sensitivity analyses to quantify the
impact sponsors’ and authors’ personal interests have on
the conclusions of a review. Finally, it has been suggested
that, as part of the process of systematic reviewing,
ethical approval of included studies or trials should be
checked on in order to identify unethical research.16 17
Systematic reviewers could hence act as whistle-blowers
when reporting any suspected misconduct.18
Objectives
The aim of this study is to examine whether systematic
reviewers apply the aforementioned procedures, and
whether they uncover and report on cases of
misconduct.
The study ﬁrst examines whether reviewers searched
for unpublished studies or tested for publication bias,
contacted authors to unearth unreported outcomes,
searched for duplicate publications, analysed the impact
of sponsors or possibles conﬂicts of interest of study
authors, checked on ethical approval of the studies and
reported on misconduct. The secondary objective was to
examine whether four major journals and the Cochrane
Library reported consistently on the issue.
METHODS
The reporting of this cross-sectional study follows the
STROBE recommendation.19 The protocol is available
from the authors.
Study design
We conducted a cross-sectional analysis of systematic
reviews published in 2013 in four general medical jour-
nals (Annals of Internal Medicine (Ann Int Med), The BMJ
(BMJ), JAMA and The Lancet (Lancet)). A random
sample of new reviews was drawn from the Cochrane
Database of Systematic Reviews (Cochrane Library) in 2013,
as Cochrane reviews are considered the gold standard in
terms of systematic reviewing.
Setting and selection of systematic reviews
Systematic reviews were identiﬁed through a PubMed
search in August 2014, using the syntax ‘systematic
review [Title] AND journal title [Journal], limit
01.01.2013 to 31.12.2013’. A computer-generated
random sequence was used to select 25 reviews pub-
lished in 2013 in the Cochrane Library (http://www.
cochranelibrary.com/cochrane-database-of-systematic-
reviews/2013-table-of-contents.html).
Reviews were selected by one of the ﬁve authors (NE)
on the basis of the review titles and abstracts. This was
checked by another author (AC). To be eligible, reviews
had to describe a literature search strategy and include
at least one trial or study. Narrative reviews or
meta-analyses without an exhaustive literature search
were not considered.
Variables
From each systematic review, we extracted the following
information: the ﬁrst author’s name and country of
afﬁliation; the number of co-authors; the name of the
journal; the title of the review; the number of databases
searched; the number of studies and study designs
included; the language limitations applied; whether or
not a protocol was registered and freely accessible; and,
ﬁnally, sources of funding and possible conﬂicts of inter-
est of the reviewers.
Furthermore, we examined whether each of the
selected reviews applied the following six procedures,
they: (1) searched for unpublished trials; (2) contacted
authors to identify unreported outcomes; (3) searched
for duplicate publications (deﬁned as a redundant
republication of an already published study, with or
without a cross-reference to the original article); (4)
analysed the impact of the sponsors of the original
studies on the conclusions of the review; (5) analysed
the impact of possible conﬂicts of interest of the authors
on the conclusions of the review; and (6) extracted
information on ethical approval of included studies. We
used the following rating system: 0=procedure not
applied, 1=partially applied, 2=fully applied (table 1).
Finally, we collected information on whether the sys-
tematic reviewers suspected, and explicitly reported on,
any misconduct in the included articles.
Bias
Data from the reviews were extracted by one author
(NE), and copied into a speciﬁcally designed spread-
sheet. Two of the co-authors checked the data (AC and
DMP). We contacted all the corresponding authors of
the reviews and asked them to conﬁrm our interpret-
ation of their methods of review. This included their
method regarding the search for unpublished trials,
their contacts with the authors, their search for dupli-
cate publications and their identiﬁcation of misconduct.
When there was discrepancy between our interpretation
and the reviewers’ answers, we used the latter. This was
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done by email, and a reminder was sent to those who
had not replied within 2 weeks.
Sample size
The capacity of systematic reviewers to identify miscon-
duct is unknown. Our hypothesis was that 5% of system-
atic reviewers would identify misconduct. Therefore, we
needed a minimum of 110 systematic reviews to allow us
to detect a prevalence of 5%, if it existed, with a margin
of error of 4% assuming an α-error of 0.05.
Statistical methods
Descriptive results are reported as numbers (propor-
tions) and median (IQR) as required. To check whether
systematic reviews were different from one journal to the
other, we performed all descriptive analyses separately
according to title of the journal. χ2 or Kruskal–Wallis
tests were applied to test the null hypothesis of homoge-
neous distribution of characteristics and outcomes. We
compared reviews from reviewers who answered our
inquiry with reviews from those who did not, and across
journals. Since Cochrane reviews were expected to be
different from those published in the journals, we per-
formed separate analyses with and without Cochrane
reviews. We did not expect missing data. Statistical sig-
niﬁcance was deﬁned as an α-error of 0.05 or less in two-
sided tests. Analyses were performed using STATAV.13.
RESULTS
Selection of reviews
We identiﬁed 136 references; 18 were excluded for dif-
ferent reasons, leaving us with 118 systematic reviews
(Ann Int Med 39A1-39; BMJ 38B1-38; JAMA 12J1-12; Lancet
10L1-10; Cochrane Library 19C1-19) (ﬁgure 1, online
supplementary appendix table 1A).
Characteristics of the reviews
The characteristics of the reviews are described in table 2,
online supplementary appendix tables 1A and 2A.
Approximately 75% of the ﬁrst authors were afﬁliated to
an English-speaking institution. The protocols of all the
Cochrane reviews were registered and available. However,
protocols were available for only 17 reviews from the
journals.
Sources of funding were declared in 110 reviews.
Among these 110, 24 declared that they had no funding
at all. All the reviews declared presence or absence of
conﬂicts of interest of the reviewers.
The median number of databases searched was four.
Additional references were searched in systematic
reviews published previously and through contacting
experts and/or authors of the original studies. Forty-two
(36%) reviews only considered the English literature,
and 6 (5%) reviews searched in Medline only. Four
(3%) reviews searched for English articles in Medline
only.A(35,39),J(5,9) The median number of articles
included per review was 28. Half of the systematic
reviews included a mix of various study designs, while
39% included only RCTs (table 2).
Outcome data
Contact with reviewers
Out of the 118 reviews, we were able to contact 111 cor-
responding authors. No valid email address was available
for seven. Eighty reviewers (72%) responded to our
inquiries.
Among the 80 reviewers who responded, 8 (10%) pro-
vided information that changed our data extraction
Table 1 Rating of the six procedures examined
Score
0 1 2
Search of unpublished
trials and/or test for
publication bias
Unpublished trials not
searched, publication bias
not tested
Unpublished trials searched
OR publication bias tested
Unpublished trials searched AND
publication bias tested or
statistically corrected
Contact with study authors Study authors not
contacted
Study authors contacted for
methodology or unspecified
reasons
Study authors contacted to unearth
unreported endpoints
Duplicate publications Duplicate publications not
searched or not mentioned
Duplicate publications
searched
Duplicate publications referenced
in the published report*
Sponsors of the studies Information on study
sponsors not reported
Information on study
sponsors reported
Impact of study sponsor(s) on the
conclusions of the review analysed
Study authors’ conflicts of
interest
Study authors’ conflicts of
interest not reported
Study authors’ conflicts of
interest reported
Impact of study authors’ conflicts of
interest on the conclusions of the
review analysed
Ethical approval Ethical approval of
included studies not
reported
Ethical approval of included
studies reported
Lack of ethical approval of included
studies reported and referenced†
Percentages may not add-up to 100% because of rounding errors.
*Also includes reports that explicitly mention that no duplicates were identified.
†Also includes reports that explicitly mention that none of the included studies lacked ethical approval.
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regarding the endpoint ‘search for unpublished trials or
test for publication bias’. One reviewer declared that, con-
trary to our assumption, unpublished trials had not been
searched in their review,B28 and seven claimed that
unpublished trials had been searched although this was
not reported in the published reviews.A(21,25,30,31),B(2,17,27)
Eleven reviewers (14%) provided information that
changed our data extraction regarding the endpoint
‘contact with authors of original studies’. One declared that
authors had not been contacted,B35 and 10 claimed that
authors had been contacted although this was not reported
in the published review.A(12,25,31,34),B(20,25,34),J(9,12),L1
Twenty-six reviewers (32%) provided information that
changed our data extraction regarding the endpoint
‘duplicate publication’. Terms used included ‘duplicate’,
‘companion article’, ‘multiple publications’, ‘articles with
overlapping datasets’, or ‘trials with identical patient
population’. Three reviewers declared that, contrary to
our assumption, they had not identiﬁed duplicate
publications,A(25,26),J3 and 23 claimed having searched
for duplicates although this was not reported in the
published review.A(16,17,21,24,27,30,31,33),B(9,10,14,20,25,27),
C(6,10,11,14,16,18),J6,L(6,9)
Five reviewers (6%) told us about suspected cases of
misconduct that were not reported in the published
review.
Characteristics of the reviews did not differ depending
on whether or not we were able to contact their authors
(table 2).
Main results
The median number of procedures applied in each
review was 2.5 (IQR, 1–3). Eleven reviews (9%) applied
no procedures at all, while no review applied all six
procedures.
Search of unpublished trials and test for publication bias
Fifty-six reviewers (47%) either searched for unpub-
lished trials or applied a statistical test to identify publi-
cation bias. Twenty-three reviewers (19%) did both.
Unpublished studies were sought for in trial registries
(eg, ClinicalTrials.gov or FDA database), or by contact-
ing experts and manufacturers. The number of unpub-
lished studies included in these reviews was
inconsistently reported. Contacting the reviewers did not
help us clarify this issue. Seven reviews (6%) only dis-
cussed the risk of publication bias, and 32 reviews (27%)
did not mention it at all (table 3).
Contact with authors to unearth unreported outcomes
Seventy-three reviewers (62%) had contacted the
authors of the original studies. Fifty-eight reviewers
(49%) had searched for unreported results from the ori-
ginal articles. The reviews rarely reported on the
number of authors contacted and the response rate. We
were not able to clarify this issue in our email exchange
with the reviewers (table 3).
Duplicate publications
Duplicate publications were sought for in 81 reviews
(69%). Twenty-two reviewers conﬁrmed that duplicates
were not sought for, and 15 did not answer our enquiry.
The number of duplicates identiﬁed was rarely men-
tioned. We failed to clarify this issue in our exchange
with the reviewers. Ten reviews (8.5%) published the ref-
erence of at least one identiﬁed duplicate.A(1,10,18,38),C
(1,4,6,12),J(2,9)
Sponsors
Twenty-seven reviews (23%) reported on the sources of
funding for the studies. Six reviewers (5%) analysed the
Figure 1 Flowchart of retrieved and analysed systemic reviews.
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impact of sponsors on the results of the review.B
(4,15,26,32),J12,L8 One reviewer claimed that sponsor bias
was unlikely,L8 while three were unable to identify any
sponsor bias.B(4,15),J12 Finally, two reviews identiﬁed
sponsor bias (see online supplementary appendix table
3A).B26,32
Conflicts of interest of authors
Five reviewers reported on conﬂicts of interest of the
authors of the studies.A(8,14),B20,C(8,14) None of them
used this information to perform subgroup analyses.
One review mentioned conﬂicts of interest as a possible
explanation for their (biased) ﬁndings.A8 In three
reviews, the afﬁliations of the authors were summarised
and potential conﬂicts of interest clearly identiﬁed.B20,C
(8,14) Finally, the appendix table of one of the reviews
showed that one study might have suffered from a ‘sig-
niﬁcant conﬂict of interest’ .A4
Ethical approval of the studies
Three reviews looked at whether or not ethical approval
had been sought for (see online supplementary
appendix table 3A).B(27,37),C10 Two reviews explicitly
reported that all included studies had received ethical
approval.B(27 37) The third review reported extensively
on which studies had or had not provided any informa-
tion on ethical approval or patient consent.C10
Outcomes did not differ according to whether or not
we were able to contact the reviewers (table 3).
Table 2 Characteristics of the systematic reviews analysed
ALL Answer No answer
p ValueN Per cent N Per cent N Per cent
Number of systematic reviews 118 100 80 68 38 32
Number of co-authors 0.240
Median (IQR) 6 (5–9) 6 (4–7.5) 6 (5–9)
Country of affiliation of 1st author 0.969
USA 42 36 27 34 15 39
UK 23 19 16 20 7 18
Canada 21 18 14 18 7 18
Australia 4 3 3 4 1 3
Others 28 24 20 25 8 21
Protocol registration/accessibility 0.513
No mention of protocol 82 69 53 66 29 76
Protocol exists/not freely accessible 3 3 2 3 1 3
Protocol exists/freely accessible 33 28 25 31 8 21
Source of funding of systematic review 0.420
Not reported 8 7 7 9 1 3
Reported that no funding was received 24 20 15 19 9 24
Reported that funding was received with details 86 73 58 73 28 74
Conflicts of interests of systematic reviewers 0.130
Not reported 0 0 0 0 0 0
Reported that there were none 42 36 33 41 9 24
Reported and detailed in the published report 61 52 39 49 22 58
Reported elsewhere (eg, online) 15 13 8 10 7 18
Number of databases searched 0.637
Median (IQR) 4 (3–7) 4 (3–7) 4 (3–6)
Language limitations applied 0.569
None 56 47 35 44 21 55
English only 42 36 30 38 12 32
Limitations to other languages 7 6 6 8 1 3
Not specified 13 11 9 11 4 11
Number of studies included 0.804
Median (IQR) 28 (12–57) 28 (12–59) 34 (12–55)
Study designs examined 0.312
RCT only 46 39 32 40 14 37
Cohort prospective only 5 4 4 5 1 3
Diagnostic studies only 5 4 5 6 0 0
Various designs 62 53 39 49 23 61
Answer: reviews in which extracted data were confirmed by reviewers. No answer: reviews in which extracted data were not confirmed by
reviewers. p Value testing the null hypothesis of equal distribution between the reviews for which the author responded to our inquiries and
those who did not. Statistical tests: χ2 test or Kruskal-Wallis equality of population rank tests, as appropriate.
RCT, randomised controlled trials.
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Suspicion of misconduct
Two reviewers suspected research misconduct in the arti-
cles included in their review and reported it
accordingly.B31,J12 Contacting the other reviewers
allowed us to uncover ﬁve additional cases of possible
misconduct. Four agreed to be cited here;A26,B33,C16,L1
while one preferred to remain anonymous.
Data falsiﬁcation was suspected in three reviews.A26,C16,
J12 One review, looking at the association of hydroxyethyl
starch administration with mortality or acute kidney
injury of critically ill patients,J12 included seven articles
co-authored by Joachim Boldt. However, a survey per-
formed in 2010, and focusing on Boldt’s research pub-
lished between 1999 and 2010, had led to the retraction
of 80 of his articles due to data fabrication and lack of
ethical approval.20 The seven articles co-authored by
Boldt were kept in the review as they had been pub-
lished before 1999. Nonetheless, the reviewers performed
sensitivity analyses excluding these seven articles, and
showed a signiﬁcant increase in the risk of mortality and
acute kidney injury with hydroxyethyl starch solutions
that was not apparent in Boldt’s articles.
The second review examined different techniques of
sperm selection for assisted reproduction. The reviewers
suspected data manipulation in one study since its
authors reported non-signiﬁcant differences between
the number of oocytes retrieved and embryos trans-
ferred while the p-value, when recalculated by the
reviewers, was statistically signiﬁcant.C16
The third review (on management strategies for asymp-
tomatic carotid stenosis) reported that misconduct had
been suspected based on the ‘differences in data
between the published SAPPGIRE trial and the
re-analysed data posted on the FDA website’.A26 Although
this information was not provided in the published
review, it was available in the full report online (http://
www.ahrq.gov/research/ﬁndings/ta/carotidstenosis/caro
tidstenosis.pdf).
Table 3 Application of the procedures to counter-balance some common research malpractices
ALL Answer No answer p Value
N Per cent N Per cent N Per cent
Number of systematic reviews 118 100 80 68 38 32
Search of unpublished trials and/or test for publication bias 0.914
Publication bias discussed only or not mentioned 39 33 26 33 13 34
Unpublished trials searched OR publication bias tested 56 47 39 49 17 45
Unpublished trials searched AND publication bias tested 23 19 15 19 8 21
Contact with authors of the studies 0.427
Study authors not contacted 45 38 28 35 17 45
Study authors contacted for method or unspecified reason 15 13 12 15 3 8
Study authors contacted for unreported outcomes 58 49 40 50 18 47
Duplicate publications 0.057
Not searched or not mentioned 37 31 21 26 16 42
Searched and found, not referenced OR no mention of results 71 60 54 68 17 45
Searched, found and referenced 10 8 5 6 5 13
Sponsors of the studies 0.809
Not mentioned 91 77 63 79 28 74
Information extracted 21 18 13 16 8 21
Information extracted and subgroup analyses performed 6 5 4 5 2 5
Conflicts of interests of study authors 0.703
Not mentioned 113 96 77 96 36 95
Information extracted 5 4 3 4 2 5
Information extracted and subgroup analyses performed 0 0 0 0 0 0
Ethical approval of included studies 0.481
Not mentioned 115 97 77 96 38 100
Information extracted 3 3 3 4 0 0
Information extracted and subgroup analyses performed 0 0 0 0 0 0
Number of procedures applied 0.403
None 11 9 6 8 5 13
1 or 2 procedures 48 41 34 43 14 37
3 or 4 procedures 56 47 38 48 18 47
5 procedures 3 3 2 3 1 3
Median (IQR) 2.5 (1–3) 2.5 (2–3) 2.5 (1–3)
Explicit mention of misconduct by reviewers 0.296
No, or not mentioned 111 94 74 93 37 97
Yes 7 6 6 8 1 3
Answer: reviews in which extracted data were confirmed by reviewers. No answer: reviews in which extracted data were not confirmed by
reviewers. p Value testing the null hypothesis of equal distribution between the reviews for which the authors responded to our inquiry and
those who did not (χ2 test). Percentages may not add-up to 100% because of rounding errors.
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Intentional selective reporting of outcomes was sus-
pected in two reviews.B31 In one review that examined
early interventions to prevent psychosis, the reviewers
identiﬁed, discussed and referenced three articles that
did not report on all the outcomes.B31 In the second
review, the corresponding reviewer (who preferred to
remain anonymous) revealed that he ‘knew of two situa-
tions in which authors knew what the results showed if
they used standard categories (of outcome) but did not
publish them because there was no relationship, or not
the one they had hoped to ﬁnd.’
Plagiarism was identiﬁed in one review examining
the epidemiology of Alzheimer’s disease and other
forms of dementia in China.L1 According to the
reviewers, they had identiﬁed a ‘copy-paste-like dupli-
cate publication of the same paper published two or
more times, with the same results and sometimes even
different authors’. This information was not reported
in the published review. The corresponding reviewer
explained that they ‘had a brief discussion…about
what to do about those ﬁndings and whether to
mention them in the paper…We did not think that we
should be distracted from our main goal, so we felt
that it was better to leave it to qualiﬁed bodies and
specialised committees on research malpractice to
address this problem separately.’
Finally, one reviewer told us that “there were some
‘suspected misconduct’ in original studies on which we
performed sensitivity analysis (best case—worst case)”.
The review mentioned that some studies were of poor
quality, but it did not speciﬁcally mention suspicion of
misconduct.B33
The median number of studies included in the
reviews that detected misconduct was 56 (IQR, 11–97),
and was 28 (IQR, 12–57) in the reviews that did not
detect misconduct. The difference did not reach statis-
tical signiﬁcance.
Secondary endpoints
The reviews published in the four medical journals dif-
fered in most characteristics examined in this paper. The
reviews published in the Cochrane Library differed from all
the other reviews (see online supplementary appendix
table 2A). There were also differences in procedures
applied across the journals (see online supplementary
appendix table 4A). The only three reviews that had
extracted data on ethical approval for the studies were
published in the BMJ (2) and in the Cochrane Library (1).
Finally, one review from the BMJ and one review from
JAMA explicitly mentioned potential misconduct.
DISCUSSION
Statement of principal findings
This analysis conﬁrms some issues and highlights new
ones. The risk related to double counting of participants
due to duplicate publications and the risk of selective
reporting of outcomes are reasonably well recognised.
More than half of the reviews applied procedures to
reduce the impact of these malpractices. The problem
of conﬂicts of interest remains underestimated, and
ethical approval of the original studies is overlooked.
Although systematic reviewers are in a privileged pos-
ition to unearth misconduct such as copy-paste-like pla-
giarism, intentional selective data reporting and data
fabrication or falsiﬁcation, they do not systematically
report them. Finally, editors have a role to play in
improving and implementing rigorous procedures for
the reporting of systematic reviews to counter-balance
the impact of research malpractice.
Comparison with other similar analyses
Our study conﬁrms that systematic reviewers are able to
identify publications dealing with the same cohort of
patients.15 However, 20% of reviews under consideration
failed to report having searched for duplicates. Only ten
of them provided the references to some of the identi-
ﬁed duplicates. It remains unclear whether reviewers do
not consider duplicate publication worth disclosing or
whether they are unsure on how to address the issue.
Finally, there is no widely accepted deﬁnition of the
term ‘duplicate’, which, in turn, adds to the confusion.
For example, a number of reviewers used the term
‘duplicate’ to describe identical references identiﬁed
more than once through the search process.
Selective publication of studies, and selective reporting
of outcomes, have been examined previously.21–26 This
led the BMJ to call for « publishing yet unpublished com-
pleted trials and/or correcting or republishing misreported
trials ».27 Other ways to address this issue include registra-
tion of the study protocols,28 searching for unpublished
trials8 29 and contacting authors to retrieve unreported
outcomes.30 31 Our analyses show that 70% of systematic
reviewers are aware of these malpractices, although 10%
failed to report them explicitly. As described before,32
most reviewers did not report on the number of unpub-
lished articles included in their analyses, the number of
authors contacted and the response rate.
Despite the obvious risk of research conclusions
favouring a sponsor,33 subgroup analyses on funding
were rarely performed. Sponsor bias may overlap with
other malpractices such as selective reporting,34 35
redundant publication9 or failure to publish completed
research.35 It may also overlap with conﬂicts of interest
of the authors of the original studies, an issue that
remains largely overlooked in these systematic reviews.
There is a general understanding that authors with con-
ﬂicts of interest are likely to present conclusions in
favour of their own interests.12 36 Although most journals
now ask for a complete and overt declaration of conﬂicts
of interest from all authors, this crucial information
remains unclearly reported. This may explain why we
found no reviews that performed subgroup analyses on
this issue.
Ten years ago, Weingarten proposed that ethical
approval of studies should be checked during the
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process of systematic reviewing.16 However, our study
shows that only three reviews reported having done so.
The need to report ethical approval in original studies
has only recently been highlighted. A case of massive
fraud in anaesthesiology,20 in which informed consent
from patients and formal approval by ethics committee
were fabricated, only shows how difﬁcult a task it will be.
The most striking ﬁnding was that although seven sys-
tematic reviews suspected misconduct in original studies,
ﬁve of them did not report it, one reported it without
further comment and only one reported overtly on the
suspicion. This illustrates that reviewers do not consider
themselves entitled to make an allegation, although they
are in a privileged position to identify misconduct. The
fact that one reviewer preferred to remain anonymous
further illustrates the reluctance to openly report on
misconduct.
Strengths and weaknesses
We used a clear and reproducible sampling method that
was not limited to any medical specialty. The data ana-
lysed had been conﬁrmed by the reviewers. This allowed
us to quantify the proportion of procedures that were
implemented but not reported by the reviewers. Finally,
to our knowledge, this is the ﬁrst analysis of the proce-
dures used by systematic reviewers to deal with research
malpractice and misconduct. Qualitative answers of the
reviewers were very informative.
We selected systematic reviews from four major
medical journals and the Cochrane Library, which is con-
sidered the gold standard in terms of systematic review-
ing. We can reasonably assume that the problems
identiﬁed are at least as serious in other medical jour-
nals. Systematic reviews that were not identiﬁed as such
in their titles were not included. However, including
these reviews would not have changed our ﬁndings.
Only one reminder was sent to the reviewers, since the
response rate was reasonably high. Furthermore, the
characteristics of the systematic reviews did not differ
between reviews for which authors responded or not.
We did not ask the reviewers to conﬁrm all their data
but focused on the information that we considered
unclear. It is possible that some of the reviewers had
indeed extracted information on sponsors’ and authors’
conﬂicts of interest, as well as ethical approval of the
studies, but failed to report them. A number of proce-
dures applied and instances of misconduct came to light
through our personal contacts with the reviewers. Our
results might therefore be underestimated. On the other
hand, it is possible that some reviewers pretended having
applied some procedures although they had not. This
would have led to an overestimation of the number of
procedures applied. The major weakness of this study
lies in the lack of an accepted deﬁnition of ‘research
misconduct’. It is possible that some reviewers might
have hesitated to disclose suspected misconduct, leading
to an underestimation of the prevalence of misconduct
identiﬁed. Finally, we have used the ‘preliminary
taxonomy of research misconduct’ proposed by Smith in
2000,6 and categorised all common minor misconduct
as ‘malpractices’. Some may disagree with our
classiﬁcation.
Conclusions and research agenda
The PRISMA guideline has improved the reporting of
systematic reviews.37 PRISMA-P aims to improve the
robustness of the protocols of systematic reviews.38 The
17-items list mentions the assessment of meta-bias(es),
such as publication bias across studies, and selective
outcome reporting within studies. However, the list is
not concerned with authors’ conﬂicts of interest, spon-
sors, ethical approval of original studies, duplicate publi-
cations or the reporting of suspected misconduct. The
MECIR project deﬁnes 118 criteria classiﬁed as ‘manda-
tory’ or ‘highly desirable’, to ensure transparent report-
ing in a Cochrane review.39 Among these criteria,
publication and outcome reporting bias, funding
sources as well as conﬂicts of interest are highlighted as
‘mandatory’ to report on. However, ethical approval for
studies is not. Most importantly, neither of the two
recommendations explicitly describes what should be
considered misconduct, what kind of misconduct must
be reported, to whom, and how.
We have previously shown how systematic reviewers
can test the impact of fraudulent data on systematic
reviews,40 identify redundant research41 and identify
references that should have been retracted.42 This paper
suggests that systematic reviewers may have additional
roles to play. They may want to apply speciﬁc procedures
to protect their analyses from common malpractices in
the original research, and they may want to identify and
report on suspected misconduct. However, they do not
seem to be ready to act as whistle-blowers. The need for
explicit guidelines on what reviewers should do once
misconduct has been suspected or identiﬁed has already
been highlighted.18 These guidelines remain to be
deﬁned and implemented. The proper procedure would
require the reviewer to request the institution where the
research was conducted to investigate on the suspected
misconduct, as the institution holds the legal legitimacy.
Whether alternative procedures could be applied should
be discussed. For example, they may include contacting
the editor-in-chief of the journal where the suspected
paper was originally published, or the editor-in-chief
where the systematic review will eventually be published.
Future research should explore the application of add-
itional protective procedures such as checking for the
adherence of each study to its protocol, or the handling
of outlier results, and quantify the impact of these mea-
sures on the conclusions of the reviews. Finally, potential
risks of false reporting of misconduct need to be
studied.
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